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Abstract   
Background: Systemic Sclerosis (SSc) has the highest case-specific mortality of any 
rheumatic disease and has no effective therapy. A clear manifestation of SSc is the presence 
of auto-antibodies. However, the origin of autoantibody-producing B lymphocytes and 
mechanisms of their activation, auto-antibody production and role remain unclear.  
Objective: To identify mechanisms that contribute to pathogenic B cell generation, 
involvement in SSc and assess the altered distribution and function of B cells in patients. 
Methods:  Multi-colour flow cytometry was used to determine B cell subset distribution, 
cytokine production and tolerance induction in SSc patients and healthy controls. Cytokine 
production following stimulation of the cells ex vivo was carried out by multiplex analysis. 
Results: The study reveals a range of defects in B lymphocyte tolerance and cytokine 
production in SSc. Evidence is provided for altered distribution of transitional B cell subsets, 
increased production of IL-6 and IL-8 and defective tolerance induction in SSc B cells. In 
addition, the study reveals that B cells in SSc have a reduced ability to produce IL-10 when 
stimulated through innate immune pathways. In contrast to healthy individuals, tolerance 
checkpoints in SSc patients fail to suppress the emergence of B cells that produce 
autoantibodies with specificity to the Scl-70 antigen, a specificity strongly associated with 
SSc. These defects are paralleled by altered intracellular signalling and apoptosis following B 
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Conclusion: The study provides new insights into mechanisms underlying defective B 
lymphocyte responses in patients with SSc and their contribution to pathology. 
 
INTRODUCTION 
Systemic sclerosis (SSc) is a severe inflammatory disease characterized by excessive 
extracellular matrix (ECM) deposition in the skin and visceral organs (1). It has complex 
pathogenesis with two major hallmarks: autoimmunity and inflammation leading to 
widespread damage to blood vessels and progressive interstitial and perivascular fibrosis (2).  
 
A key feature of autoimmunity in SSc is high levels of auto-antibodies (auto-Abs) to nuclear 
proteins including topoisomerase I enzyme, centromere and RNA polymerase and endothelial 
cell and platelet derived growth factor receptor (1, 3). Evidence for pathogenic roles of these 
auto-Abs comes from studies revealing the association between their specificity and which 
tissues and organs are involved. Importantly also, these auto-Abs appear prior to disease 
onset. Furthermore, B lymphocytes accumulate at sites of disease, around small vessels in the 
skin (4) and in alveolar interstitium in patients with lung involvement (5). In addition to 
producing auto-Abs, B lymphocytes contribute to fibrosis through producing interleukin 6 
(IL-6) (6).  
 
The role played by B lymphocytes in SSc is supported by studies of disease pathogenesis in 
mouse models (7-9) and the success of treating patients with rituximab, a chimeric 
monoclonal antibody against human CD20 (10, 11). In the tight-skin mouse model of SSc 
that is associated with constitutive CD19-mediated signaling (7, 12), inhibition of CD19 
expression abrogates auto-Ab production, IL-6 production by B cells and ameliorate skin 
fibrosis (7, 8). Similar effects were noted when CD19 expression was suppressed in the 
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and diffuse disease who are positive for anti-Scl70 auto-Abs benefit significantly from 
treatment with rituximab (10). Thus, no patient receiving rituximab exhibited lung function 
deterioration, whereas 5 out of 6 placebo-treated patients had a worsening of their disease. 
Additionally, skin thickening, collagen deposition in the skin and health quality improved in 
rituximab-treated patients but not in placebo-treated patients (10-14). Furthermore, rituximab 
reduced the level of plasma IL-6, activity index, depleted skin B lymphocytes and reduced 
dermal myofibroblasts and hyalinised collagen in the skin (15).  
 
The cause of defective B cell responses in SSc remains unclear. However, defective tolerance 
and deregulation of autoreactive B cell responses are potential causes of B cell-mediated 
pathology. High affinity self-reactive B cells are normally deleted in the bone marrow but 
some that recognize self with low affinity or those that do not encounter self-antigens in the 
bone marrow escape censure and migrate to the periphery as transitional B cells. Migrant 
“transitional” B cells go through series of tolerance checkpoints and maturational phases to 
become mature B cells. This pathway was initially described in mice as immature B cells 
transiting to the spleen to mature into to B cell receptor- (BCR) responsive cells to antigen 
engagement (16). Murine transitional B cells are distinguishable from mature cells based on 
the level of CD23, CD21 and the developmental marker CD24 expression (17). In humans, 
recent studies from a number of laboratories including ours have revealed that transitional 
human B cells (CD24highCD38high) do not constitute a single population but can be divided 
into 4 subsets (18). These subsets have subtle differences in maturational and tolerance status 
and capacity to produce IL-10 and IL-6 (18, 19). The current study was carried out to explore 
if defects in the maturation of, or tolerance induction in B cells at the transitional stage could 
relate to the emergence of high affinity pathogenic B cells in patients. Transitional B cells 
were studied for their ability to produce IL-6 as its production is a key mechanism by which 
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produce IL-10 was studied to assess their ability to be involved in immune regulation (19, 
20). We used a multi-colour flow cytometry and a secretome profiling approach to 
characterize the distribution and functional characteristics of B cells in SSc to identify 





All patients fulfilled the 2013 EULAR/ACR criteria for SSc (21). Disease subsets were 
defined as patients with limited cutaneous SSc (lcSSc) when skin thickening was present 
distal to elbows and knees and as diffuse cutaneous SSc (dsSSc) when skin thickening 
affected both distal and proximal areas. Blood samples from 88 patients with SSc attending 
the clinics were obtained for the purpose of this study after their informed consents. Patients 
with interstitial lung disease were diagnosed based on characteristic changes visualised by 
high-resolution computed tomography (CT). Pulmonary arterial hypertension was diagnosed 
by right heart catheterization with mean pulmonary artery pressure of ≥25 mm Hg and normal 
pulmonary capillary wedge pressure. Scleroderma renal crisis (SRC) was defined as new-
onset systemic hypertension >150/85 mm Hg and a documented decrease in estimated 
glomerular filtration rate of ≥30% or confirmed features on renal biopsy (22). Blood samples 
from 17 healthy controls (HCs) (mean age 40.2±11.3 years; 25-60 years) were also included 
for comparisons. Some of the tested samples from both patients and controls were studied on 
multiple occasions. The study was approved by the London-Hampstead National Research 
Ethics Service Committee (REC reference: 6398) and was conducted in compliance with the 
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B lymphocyte enrichment 
B lymphocytes were enriched from whole blood by negative selection using the EasySep 
Human B Cell Enrichment Kit (StemCell Technologies, Grenoble, France). All experiments 
presented in this study were carried out using freshly-enriched B lymphocytes from blood 
samples taken on the same day. The protocol of B cell enrichment involves using a cocktail 
of monoclonal antibodies (mAbs) with dual specificity for non-B cell components of blood 
mononuclear cells (MNCs) and red blood cells (RBCs). The cocktail aggregates all non-B 
cells with RBCs and these are then separated on Ficoll-Paque. The protocol is fast and purity 
of enriched B cells is >95%. 
Cell staining and flow cytometry 
Enriched B cells were stained with combinations of fluorochrome-conjugated antibodies (18). 
mAbs were purchased from the suppliers indicated as follows: APC-eFlour780-conjugated 
anti-human CD10 (Clone SN5c), PE-Cy5.5-anti-human CD19 (Clone: HIB19), PE-Cy7-anti-
human CD32 (Clone 6C4), FITC-anti-human IgD (Clone: IA6-2), eFlour 450-anti-human 
CD21 (Clone: HB5) and PE-anti-human CD24 (Clone: eBioSN3) mAbs were all from 
eBioscience. Brilliant Violet 605-anti-human IgM (Clone: MHM-88), brilliant Violet 785-
anti-human CD19 (Clone: HIB19) and brilliant Violet 711-anti-human CD27 (Clone: O323) 
were from BioLegend. PerCP-Cy5.5-anti-CD38 mAb (Clone: HIT2) was from BD 
Biosciences. For intracellular cytokines, stained cells were fixed, permeabilized and stained 
with either APC-anti-human IL-6 mAb (Clone: MQ2-13A5), APC-anti-human IL-10 mAb 
(Clone: JES3-9D7) (both from BD Bioscience) and were assessed by LSR-Fortessa FACS 
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For measuring the frequency of IL-6- or IL-10-producing B lymphocytes, enriched cells were 
stimulated with PMA (50ng/mL) and Ionomycin (250ng/mL) in the presence of Golgi-Plug 
for 6 hours at 37oC (BIO-RAD) and then stained with different combinations of 
fluorochrome-conjugated mAbs and assessed by LSR-Fortessa. For measuring IL-10 
production in the supernatant of ex vivo stimulated B cells, enriched cells were cultured with 
mitomycin C-treated mouse L-fibroblasts transfected with cDNA for human CD40L. In some 
experiments, the cells were stimulated with the soluble TLR9 agonist CpG-ODN either alone 
or in the presence of 10μg/mL of mouse mAb to human CD40 (clone G28-5) pre-coated onto 
culture plates. The cells were cultured for 72 hours at 37oC. For co-culture experiments 
involving the CD40L-transfected L-fibroblasts, these were first incubated with 10µg/mL 
mitomycin C for 2 hours then enriched B cells added at a ratio of 1:5 mouse L-fibroblasts: B 
cells. Culture supernatants were collected, centrifuged and tested for cytokine levels using 
Meso Scale Discovery (MSD) multiplex kits as described (23). 
 
Apoptosis, either spontaneous or following engaging the BCR with 25µg/mL goat F(ab’)2 
anti-human IgM (Jackson ImmunoReseach) for 8 hours at 37°C, was measured by staining 
the cells with FITC-conjugated-Annexin-V (BioLegend). 
 
For measuring phospho-STAT3 and phospho-NF-κB p65, enriched B cells were rested at 
37oC for 3 hours and then stimulated either with anti-CD40 mAb (10ug/mL), CpG-ODN 
(1uM) or the combination of both for 10 minutes. The cells were fixed, permeabilized and 
stained with either Alexa 488-conjugated anti-phospho-STAT3 mAb (Clone: D3A7) or Alexa 
488-conjugated anti-phospho-NF-κB p65 mAb (Clone: 93H1) (Cell Signaling Technology) 
and then with different combinations of conjugated mAbs for surface proteins. The results 
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Detection and quantification of autoantibody-producing B cells 
ELISpot assay kits were obtained from Mabtech (Germany). The assay was performed 
according to the manufacturer’s instructions and used to detect the frequency of anti-Scl-70 
autoantibody-secreting B cells in FACS-sorted B cell subsets from patients with SSc.  
Membranes were coated overnight at 4oC with 10µg/ml of scl-70 and FACS-sorted B cell 
subsets left to settle on the coated membranes for 20 hours at 37oC. The membranes were 
washed and biotinylated antibody specific for human IgM added followed by streptavidin-
HRP conjugate. Spots identified were for IgM antibodies specific for Scl-70 antigen secreted 
by B cells revealed with the HRP substrate 3,3',5,5'-Tetramethylbenzidine (TMB). The 
number of spots on each membrane was counted and analysed using an automated AID 
ELISpot Reader System. 
Statistical analyses 
 
All data are presented as the mean±standard error of the mean (SEM). Statistical analyses 
were performed using GraphPad Prism version 6.05 (Graph Pad software, San Diego, CA). 
Student’s t-test was used for comparing patients and the HCs and data considered significant 




The demographic and clinical profiles of the SSc patient cohort studied are summarised in 
Supplementary Table 1. The cohort included 88 patients; 74 (84.1%) were females. Forty 
patients (45.5%) had diffuse cutaneous SSc (dcSSc) and 48 (54.5%) limited cutaneous SSc 
(lcSSc). The dcSSc group had a mean age of 49±11.9 years (range 25-75 years) and disease 
duration of 7.7±7 years (1-31 years). The mean age of patients in the lcSSc group was 
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four patients had anti-centromere antibodies (27.3%) and fifteen (17.0%) anti-RNA 
polymerase antibodies. Six patients (6.8%) had anti-U3RNP auto-antibodies (auto-Abs), five 
(5.7%) anti-U1RNP auto-Abs, ten (11.4%) had unidentified anti-nuclear auto-Abs (ANA), 
four (4.5%) were ANA negative, one (1.1%) had anti-Jo1 auto-Abs and one patient had 
antiPM-Scl auto-Abs. Twenty three patients (26.1%) had interstitial lung disease and the 
majority seropositive for anti-Scl70 auto-Abs (n= 22; 25%). Two patients (2.3%) had SRC 
and 4 (4.5%) pulmonary arterial hypertension. Forty seven of the patients (53.4%) were 
treated with immunosuppressive agents including mycophenolate mofetil, 30 patients, or 
methotrexate, 7 patients (24). A majority of the patients who were not on immunosuppressive 
drugs had lcSSc (n=33).  
 
Altered distribution B cell subsets in patients with SSc  
To explore the role of B cells in SSc pathogenesis and mechanisms that could explain the 
expansion of autoreactive B cells, we first determined total numbers of B cells and 
distribution of subsets in the patients and HCs. The results showed that patients with SSc, 
generally, had higher numbers of B cells compared with the HCs (153.7±32.9 vs. 99.2±20.3 
cells/µL blood, respectively; P<0.01). When B cell subsets were categorised based on CD24 
and CD38 expression, the data showed that the patients had significantly more transitional B 
cells (CD24hiCD38hi) (19.85±1.87 cells/µL blood corresponding to 13.6±0.93% of total B 
cells) compared with the HCs (7.04.5±1.09 cells/µL blood corresponding to 6.81±0.62% of 
total B cells; P<0.001) (Figure 1A). However, the percentage of mature naïve (CD24+CD38+) 
and memory B cell numbers (CD24hiCD38+) was lower in the patients (85.57±6.21 cells/µL 
blood and 21.66 ± 2.15 cells/µL blood corresponding to 58.7±2.4% and 14.81±1.18% total B 
cells, respectively) compared with the HCs (68±4.85 cells/µL blood and 17.72±1.66 cells/µL 
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P=0.056). The increase in transitional B cells in SSc patients is consistent with other 
autoimmune diseases, such as systemic lupus erythematosus and Sjögren’s syndrome (18).  
 
We next carried out studies to determine numbers, responses and regulation of transitional B 
cell subsets to determine why they are increased in the SSc. Transitional B cells go through a 
series of developmental stages and tolerance checkpoints and, therefore, identifying defects 
in any of these stages could provide insights into specific defects in regulatory/maturation. 
We recently categorized transitional CD24highCD38high B cells into 4 subsets using a 10-color 
flow cytometry with FLOCK (Flow clustering without K) (18). The 4 subsets are 
distinguishable based on the expression of CD27, CD10, CD21, IgM, IgD and CD32 within 
CD24highCD38high B cells. Transitional subset 1 (T1) of B cells, expresses high levels of IgM, 
CD10 and CD32 and low levels of IgD, and CD21. Subset 2 (T2), expresses medium levels 
of IgM, IgD, CD10 and CD32 but high levels of CD21. T3 expresses low levels of IgM, IgD, 
CD10, CD21 and CD32 (Fig. 1B). Finally, one subset of transitional B cells expresses high 
levels of CD27, CD24 and CD38, and was designated transitional CD27+ B cells (18). The 
current study revealed that SSc patients have significantly more T1 B cells than HCs 
(1.32±0.21 vs. 0.33±0.06 cells/µL blood corresponding to 11.2±1.0% vs. 6.7±0.5% of 
transitional B cells; P<0.01) (Fig. 1B, the scatter graph panels). In contrast, there was an 
increase in the total number but a decrease in the frequency of T2 cells in patients (4.87±0.78 
vs. 2.52±0.57 cells/µL blood corresponding to 39.8±1.8% vs. 49.0±3.2% of transitional B 
cells; P<0.05). There was no differences in the frequency of T3 cells. There was, however, a 
trend towards increased CD27+ transitional B cells in the patients but this was not statistically 
significant (1.82±0.42 and 0.70±0.16 cells/µL blood corresponding to 21.7±5.0% and 
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Increased IL-6-producing transitional B cells in patients with SSc  
To assess whether the response of B cell in patients with SSc is different from HCs, we 
studied cytokine production by the cells. Enriched B cells were activated with PMA and 
Ionomycin in the presence of Golgi-Plug and stained for intracellular IL-6. FACS analyses 
showed that the number of IL-6+ B cells was higher in patients compared with HCs (51.8±7 
vs. 22.8±6.2 cells/µL blood corresponding to 35.4±4% vs. 22.5±5.5%, of total B cells) (Fig. 
2A). The number of IL-6+ cells was also higher in transitional, mature naïve and memory B 
cells in the patients (Fig. 2B). The number and frequency of IL-6+ transitional B cells were 
2.8±0.7 cells/µL blood corresponding to 14.0±3.1% of transitional B cells in the patients 
compared with 0.5±0.13 cells/µL blood corresponding to 6.7±1.0% of transitional B cells in 
the HCs (P<0.01 and <0.05, respectively). When the number of IL6+ transitional B cell 
subsets was determined, the frequency for IL-6+ T1, T2 and T3 B cells in the SSc patients 
were 15.0±2.4%, 25.1±3.9% and 23.9±4.0% respectively. These were significantly higher 
than the HCs at 5.8±1.7%, 10.3±2.2% (P<0.01) and 10.7±2.4% (P<0.05), respectively) (Fig. 
2C). 
 
The SSc B cell profiles and frequencies revealed associations with disease severity and 
symptoms. For example, SSc patients with severe lung fibrosis had more IL-6+ B cells in all 
the subsets compared with patients with mild disease. Similarly, patients with dcSSc had 
more IL-6+ B cells than patients with lcSSC (Supplementary Figure 2). Furthermore, serum 
from anti-Scl-70+ patients had more IL-6+ B cells than those without this auto-Ab. However, 
these differences were not statistically significant. 
 
Altered IL-10 production by B cells from SSc patients in response to stimulation  
Transitional B cells are normally purged from most self-reactive cells by passing through a 
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transitional B cells, however, survive this censorship and mature as polyreactive B cells. 
These cells are believed to participate in innate immunity as a first line of defence against 
infections and become polyreactive IgM-producing B cells, or mature to follicular/marginal 
zone B cells. These “natural” polyreactive B cells are, therefore, proposed to be important for 
immunity and, some, have been shown to develop to regulatory B cells (Bregs) that produce 
IL-10 (25). However, some transitional B cells can also become high affinity autoreactive B 
cells and contribute to pathology in patients with autoimmune diseases (20). To determine 
whether the increase in the number of IL-6+ B cells reflects a reduction in IL-10-producing in 
SSc, we determined the frequency of IL-10+ B cells. These analyses revealed that patients 
with SSc had more ex vivo-activated IL-10+ B cells than the HCs (Supplementary Figure 1A). 
Results of IL-10+ B cell subset analyses showed that transitional, mature and memory B cells 
all contained more IL-10+ cells in the patients compared with the HCs although the 
differences were not statistically significant (Supplementary Figure 1B). When the frequency 
of IL-10+ B cells in transitional B cells were determined there was a trend towards increased 
IL-10+ T1 and T3 B cells in the patients compared with the HCs but the differences were not 
significant (Supplementary Figure 1C).  
 
We next assessed if the functional capacity of B cells to produce IL-10 could be impaired as 
has been reported in patients with SLE (25). For this purpose, enriched B cells were 
stimulated either through CD40 alone, TLR9 alone (with its agonist CpG-ODN) or 
stimulating the cells through both pathways simultaneously and the level of IL-10 in culture 
supernatants determined. When B cells were stimulated through CD40 alone, B cells from the 
SSc patients produced more IL-10 (144.7±31.8pg/mL) than the HCs (59.1±17.1pg/mL) 
(P<0.05) (Supplementary Figure 1D). However, when B cells were stimulated by engaging 
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significantly less IL-10 (82.0±36.0pg/mL and 44.2±18.0pg/mL, respectively) than B cells 
from the HCs (190.3±35.7pg/mL and 163.4±37.9pg/mL, respectively) (P<0.05).  
 
To determine if this reflects further functional differences between B cells from patients with 
SSc and HCs, we studied the ability of B cells to produce cytokines thought to be relevant to 
SSc pathogenesis. B cells were co-cultured for 72 hours with the mouse L-fibroblasts 
transfected with human CD40L and the level of cytokines in the culture supernatants 
measured. Results of cytokine level measurements revealed that B cells from SSc patients 
produced significantly more IL-1β and IL-8 (P<0.001 and P<0.05, respectively) and also 
GM-CSF compared with B cells from the HCs. In contrast, B cells from the patients 
produced less IL-12, IFNγ and TNFα than B cells from the HCs (Fig.  3).   
   
Altered responsiveness of transitional B cells in SSc to B cell receptor (BCR) 
engagement  
Our studies of transitional B cell responses to BCR engagement including apoptosis revealed 
subtle differences between the subsets (18). For example, there was a steady increase in the 
level of Bcl-2 expression in T1 cells through to CD27+ transitional B cells. Analysis of 
spontaneous cell death (apoptosis/necrosis), however, showed no significant differences 
between the subsets. With BCR engagement, however, there was clear evidence for a higher 
rate of apoptosis in the T1 subset compared with the other 3 subsets and also with mature B 
cells. On the basis of these findings, we proposed a pathway for an evolving maturation and 
response to BCR engagement in transitional B cells (18).  Results of studying BCR-mediated 
apoptosis in transitional B cell subsets in the current study showed notable reduction in 
apoptosis in all the subsets in the SSc patients particularly in the T1 subset (13.6±4.1) 
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cells in the patients to undergo BCR-mediated apoptosis was consistent the higher number of 
IL-6-producing B cells.   
 
Our previous studies also revealed that differences between transitional and mature B cells in 
response to stimulation is associated with altered Ca2+, PI3K and PLCγ2 signalling (18). 
Therefore, we examined signaling pathways that could relate to altered IL-6 and IL-10 
production by transitional B cells in the SSc patients following TLR9-engagement (26). For 
this purpose, we examined the phosphorylation of nuclear factor-κB (NF-κB) and signal 
transducer and activator of transcription 3 (STAT3) in transitional B cells. The 
phosphorylation of NF-κB p65 and STAT3, are key in CD40 as well as TLR9-mediated 
cytokine production. In addition, NF-κB1 represses transcription of the il-6 gene since its loss 
leads to uncontrolled RelA-driven transcription of IL-6 (27). No consistent significant 
differences were seen between unstimulated B cells from the patients and HCs in the level of 
NF-κB p65 phosphorylation (Fig. 4B). However, when the B cells were stimulated through 
the TLR9, there was a significant reduction in the phosphorylation of STAT3 in T1 and 
CD27+ transitional B cells from the SSc patients (121.8±10.4 and 177.0±22.7 in MFI) 
compared with the HCs (155.6±5.6 and 251.8±10.6, respectively) (P<0.05 for both) (Fig. 
4C).  
 
Anti-Scl-70 autoantibody-producing transitional B cells survive the T1/T2 tolerance 
checkpoint at high frequency in seropositive SSc patients  
The available evidence indicates that the BCR repertoire is different between transitional and 
mature B cells (28, 29). Thus, a major fraction of transitional B cells is polyreactive and are 
suggested to give rise to natural antibody-producing mature B cells (30). For the purpose of 
the current study, we examined differences in the frequency of B cells capable of producing 
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(31, 32). To achieve this objective, the transitional B cell subsets were FACS-sorted and 
incubated for 4 days with CpG (to mimic T cell-independent stimulation) and levels of auto-
antibody to Scl-70 produced by the different transitional B cell subsets determined by 
ELIspot. Our previous studies established that the T1 and CD27+ subsets had the highest 
frequency of transitional B cells capable of differentiating to IgM-secreting cells. 
Interestingly, however, the ELIspot results revealed that the T2 subset of transitional B cells 
in SSc patients who are seropositive for anti-Scl-70 was the subset containing most of the B 
cells that produced IgM autoantibodies that bound to the Scl-70 antigen (Fig. 5A). Consistent 
with the detection of serum anti-Scl-70 auto-antibodies in patients, the number of IgM anti-




The development of B lymphocytes in the bone marrow involves a delicate balance between 
generating a repertoire capable of combating pathogens and eliminating strongly self-reactive 
cells. Changes in this balance results either in defective immunity or, alternatively, the 
generation of pathogenic self-reactive B cells leading to autoimmune diseases (33). Despite 
the tight regulation of the B cell repertoire in the bone marrow, however, some self-reactive 
B cells escape tolerance and migrate to the periphery as part of transitional B cells. These 
cells undergo further development in the periphery including passing through a number of 
tolerance checkpoints to mature to follicular, marginal zone or regulatory B cells (16, 17, 34).  
 
Results of studies from many laboratories, including ours, show that 
polyreactive/autoreactive B lymphocytes exist in significant numbers in transitional B cells in 
healthy individuals as well as in patients with autoimmune diseases (18). However, it appears 
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become pathogenic cells are tolerized in HCs, patients with SSc show defects in the 
regulation of these cells at an early stage of their developmental program. Thus, patients with 
SSc fail to eliminate or reduce the number of IL-6-producing B cells and also cells capable of 
producing autoantibodies with specificity for the hallmark SSc auto-antigen Scl-70. 
Furthermore, the results suggest that the failure to eliminate potentially pathogenic B cells in 
patients with SSc occurs at the T1 to T2 cell maturational stage. 
 
Early studies of the phenotype and functions of murine transitional B cells revealed that three 
major subsets of these cells exist (17, 35, 36). In humans, however, the phenotype and 
biology of transitional B cells remained less well-defined than in mice. A recent study in our 
laboratories using multi-colour flow cytometry and functional assessment revealed that 4 
different subsets of human transitional B cells exist (18). The criteria set for the analysis of 
transitional B cells in the current study, established based on our earlier study, show that, 
overall, the number of transitional B cells is higher in patients with SSc than HCs. The results 
also reveal that transitional B lymphocytes in patients with SSc contain a higher frequency of 
IL-6-producing B cells than in HCs. This could be relevant for further understanding of the 
regulation of B cells and how they could be involved in the pathogenesis of SSc since IL-6 is 
implicated in key aspects of SSc disease. For example, IL-6 promotes the proliferation of T 
and B lymphocytes and monocytes and their resistance to apoptosis (37). In addition, IL-6 
reduces the suppressive functions of Treg cells (38). Furthermore, IL-6 plays a significant 
role in the development of Th1 and Th17 cells (39, 40). IL-6 production is, therefore, a key 
function through which B cells could contribute to SSc pathogenesis (10, 11, 19). This 
proposition is supported by observations that the therapeutic benefits from B cell depletion in 
murine models of autoimmune diseases and in human patients relates to reduced IL-6 
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B cells is involved in promoting the development of pathogenic Th17 in chronic autoimmune 
diseases (39).  
 
In addition to transitional B cells, the study confirmed that the frequency of IL-6-producing B 
cells is also increased in mature and memory B cells. This generalized increase in the number 
of IL-6-producing B cells could relate either to a genetic predisposition to higher IL-6 
production, or to defective censorship of transitional B cells that have the potential to mature 
to pathogenic autoantibody- and/or IL-6 producing-B cells in SSc. Perhaps, relevant to the 
latter possibility is the notable increase in the proportion of IL-6-producing transitional B 
cells as they progress from T1 to T2 cells. This may implicate a defect in the checkpoint 
mechanism(s) that regulates autoreactive T1 to T2 B cell maturation. Clearly, however, 
further studies are required to verify and explore the molecular mechanism(s) that lead to 
such an outcome. Interestingly, whereas the frequency of T1 cells was significantly higher in 
patients with SSc compared with the HCs, the frequency of T2 cells was not different 
between the two groups. These two subsets have different capacities to undergo apoptosis 
following BCR engagement. Thus, whereas T1 cells in HCs undergo apoptosis following 
BCR engagement, T2 are more resistant. In contrast, T1 cells from patients with SSc 
appeared to be resistant to BCR-mediated apoptosis. This finding is consistent with our recent 
studies of transitional B cell subsets and implies that tolerance checkpoints acting at the T1-
T2 stage of translational B cell maturation could be the stage where defective tolerance 
mechanisms result in the survival of autoreactive IL-6-producing B cells in patients with SSc. 
Any defect(s) at this stage is likely to have notable effects on the repertoire of the T2 and T3 
cells and possibly, of course, mature B cells. Indeed, our results show that the T2 subsets of 
transitional B cells in patients with SSc contained B cells that produced autoantibodies with 
specificity for the Scl-70 antigen. Based on our previous studies, this observation could 
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maturational stage in SSc. Thus, the frequency of Scl-70-specific B cells at the T1 stage is 
low to detect among the large number of polyreactive B cells. However, when most 
polyreactive T1 B cells are depleted/tolerized as they mature to T2 cells, this allows for a 
relative increase in the frequency of Scl-70-specific B cells rendering them detectable within 
the surviving T2 B cells (18). 
 
The underlying molecular mechanisms in defective tolerization of Scl-70-specific B cells, 
and perhaps other self-reactive B cells, at the T1/T2 stage in SSc remain unclear but it is 
likely to involve genetic factors that are manifested in defective intracellular signaling and/or 
enhanced IL-6 production. Interestingly, however, the preliminary studies of intracellular 
signaling did not reveal differences in basal NF-κB p65 phosphorylation between transitional 
B cells from SSc patients and HCs. However, both T1 and CD27+ B cells from the patients 
showed a trend towards reduced TLR-9 induced phosphorylation of STAT-3. These findings 
are consistent with the observation that transitional B cells in patients with SSc produced 
lower levels of IL-10 when stimulated through TLR9. 
 
Transitional B cells are proposed to also give rise to Breg cells which can suppress 
autoimmunity and chronic inflammation through IL-10-dependent and independent 
mechanisms (18, 41). Our findings with regards to the reduced ability of B cells in patients 
with SSc to produce IL-10 following TLR9 but not CD40 engagement could provide further 
clues as to the cause of defects in the regulation of B cell responses in this disease. TLR9-
signaling induces IL-10 production by naive B cells whereas CD40/BCR engagement 
enhances IL-10-production by activated B cells (26). This is important since the available 
evidence suggests that the differentiation to Breg cells occurs through two stages. During the 
initial stage of differentiation, TLR9 engagements promotes IL-10-producing B cells and then 
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defective TLR-9 induced STAT3 activation in patients with SSc but not when the cells were 
stimulated through the CD40 co-receptor (not shown). 
 
The study has also revealed that B cells from patients with SSc produce significantly higher 
levels of the pro-inflammatory cytokines GM-CSF, IL-1β and IL-8 than the HCs. It will be of 
interest to evaluate directly the pathogenic contribution of these cytokines to the disease 
process in SSc. Further investigation will also be required to define the mechanisms that lead 
to the imbalance in the maturation of transitional B cells to become IL-6-producing 
potentially-pathogenic B cells rather than IL-10-producing Breg cells in SSc.  
 
It was notable in this study that the majority of the SSc patients studied were on 
immunomodulating drugs that possibly could affect the B cell profiles seen. It is likely that 
these drugs could influence the level of IL-6 production by B cells as well as the 
number/percentage of IL-6-producing cells. A detailed study of individual patients is required 
to assess the effect of treatment with immunomodulating drugs on the B cell profiles in SSc 
as reported in our study. Additionally, the SSc B cell profiles/frequencies reported showed an 
association with disease severity/symptoms. For example, SSc patients with severe lung 
fibrosis had more IL-6+ B cells within all subsets compared with patients with mild disease 
(not shown). Similarly, patients with diffuse scleroderma had more IL-6+ B cells than patients 
with limited scleroderma (Supplementary Figure 2). Further, anti-Scl-70 positive patients had 
more IL-6+ B cells B cells than seronegative patients for the autoantibody. However, these 
differences were not statistically significant. Therefore, a larger study will be required to 
address this issue conclusively. 
 
In normal individuals, significant numbers of early immature B cells display varying degrees 
of self-reactivity/polyreactivity but the level of autoreactivity progressively declines within 
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and rheumatoid arthritis patients, our results highlight inadequate elimination of autoreactive 
B-cells in patients with autoimmune disease (43-45). The fact that very few if any spots could 
be detected in B cells from the HCs suggests that polyreactive autoantibodies are unlikely to 
have influenced our observation. However, it is not possible to completely exclude the 
possibility that some of the Scl-70 bound IgM could also bind dsDNA, insulin or, indeed, 
other self-antigens.  
 
Studies in mice and humans have provided multiple lines of evidence to indicate that defects 
in central tolerance exists in patients with autoimmune diseases. However, further studies are 
required to determine which of these defects is primary and which are secondary to the 
development of autoimmunity as well as reveal the genetic basis for any such defects. Several 
studies have suggested that effective censoring of autoreactive cells rely on multiple factors 
including self-antigen availability, avidity and the ability to cross-link the BCR and engage 
TLRs and the abundance of survival factors, particularly BAFF/B-cell activating factor (46, 
47). Further investigations will also be required to define the mechanisms that lead to the 
defect in central tolerance in SSc.  
 
In conclusion, this study sheds new lights on potential mechanisms underlying defective B 
lymphocyte selection and regulation in patients with SSc and, possibly, highlights functional 
imbalances between transitional B cells that differentiate to become protective rather than 
pathogenic B cells in the disease. Based on findings from this study a framework 
summarising predictions for pathways of transitional B cell development and possible defects 
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FIGURE LEGENDS 
Figure 1: B cell subset distribution in healthy controls (HCs) and patients with SSc. A) 
The upper panel shows the gating strategy for identifying transitional, mature and memory B 
lymphocytes in peripheral blood based on expression levels of CD24 and CD38. The middle 
panel provides the actual numbers of transitional, naïve/mature and memory B cell in each μL 
of blood in HCs and patients with SSc. The bottom histogram shows the frequency of 
transitional, naïve/mature and memory B cells in the blood of the two groups. The data is 
presented as the Mean + standard error of the mean (SEM) from experiments using blood 
from 10 HCs and 10 SSc patients. * indicates p<0.05, ** p<0.01, *** p<0.001, ns: non-
significant for statistical differences using Student’s t test. B) The top panel depicts the 
staining and gating strategies used for identifying transitional T1, T2, T3 and The CD27+ 
subsets within CD24hiCD38hi B cells as described before (18). The low scatter graph panels 
show the frequency of T1, T2, T3 and CD27+ B cells subsets within transitional B cells in the 
9 HCs and 11 patients with SSc. 
 
Figure 2: IL-6 expression in total B cells and B cell subsets in HCs and patients with 
SSc. A) The top panel depicts FACS quadrants from one HC and one SSc patient showing 
the gating strategy for identifying IL-6+ ex vivo B cells stimulated with PMA and Ionomycin. 
The lower histogram summarises the frequency of IL-6+ ex vivo B cells from the blood of 
HCs and patients with SSc. The data is presented as the Mean + SEM for 10 HCs and 11 SSc 
patients. B) The left panel is for FACS quadrant profiles of B cells from one HC and one 
patients with SSc depicting the strategy for quantifying IL-6+ transitional, naïve/mature and 
memory B cell subsets. The histogram panel on the right summarises the frequency of IL-6+ 
transitional, naïve/mature and memory B cells in 4 HCs and 10 patients with SSc. C) 
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patients with SSc. * indicates p<0.05, ** indicates p<0.01, ns: non-significant for statistical 
differences using the Student’s t test. 
 
Figure 3: Cytokine production by B lymphocytes from HCs and patients with SSc. 
Enriched B lymphocytes were cultured for 72 hours in plates pre-coated with mitomycin C-
treated mouse L-fibroblast transfected with cDNA for human CD40L. Culture supernatants 
were collected, centrifuged and tested for the cytokines shown in the figure using MSD 
Multi-Plex kits. Data represents the Mean + SEM for the indicated cytokines produced by B 
lymphocytes from 5 HCs and 10 SSC patients SSc. * indicates p<0.05, *** indicates 
p<0.001, ns: non-significant for statistical differences using Student’s t-test. 
 
Figure 4: Altered responses of transitional B cells from patients with SSc to BCR and 
TLR9 engagement.  A) Bar charts representing percentages of spontaneous (two left 
columns) or BCR-induced apoptosis (two right columns, + anti-IgM) in each chart. Apoptotic 
cells were identified by staining with Annexin V+. B cell subsets from 8 HCs and 9 patients 
with SSc were studied. The data are presented as the Mean + SEM. * indicates p<0.05, ns: 
non-significant statistical differences using the Student’s t test. B) Summary of basal NF-κB 
p65 and STAT3 phosphorylation data (with no stimulation) in transitional B cell subsets in 
HCs and SSc patients. Mean fluorescence intensity (MFI) for basal phosphorylation levels of 
NF-κB p65 and STAT3 in transitional B cell subsets from 5 HCs and 4 patients with SSc. C) 
Bar charts summarising NF-κB p65 and STAT3 phosphorylation data in transitional B cell 
subsets stimulated by engaging TLR9 with its ligandin CpG-ODN. The results are presented 
as MFI for levels of TLR-induced phosphorylation of NF-κB p65 and STAT3 in transitional 
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Figure 5: The frequency of anti-Scl-70 autoantibody-producing B cells in transitional B 
cells. A) ELIspot of IgM anti-Scl-70-producing transitional B cells in HCs and SSc patients. 
The number of transitional B cell subsets that produced anti-Scl-70/104 cells is shown. The 
results are presented as the Mean+SEM obtained from experiments using blood from 4 HCs, 
6 SSc patients who were seropositive and 6 SSc patients who were seronegative for anti-Scl-
70 autoantibodies. * indicates p<0.05, ** p<0.01, *** p<0.001, ns: non-significant for 
statistical differences using Student’s t test. B) Cartoon depicting a proposed developmental 
program for transitional B cells in health and in SSc. Transitional B lymphocytes migrate 
from the bone marrow to become follicular, marginal zone or regulatory B cells. Transitional 
B cells undergo a series of maturational events and tolerance checkpoints to prevent the 
emergence of high affinity self-reactive B cells. The model envisions that during maturation 
in healthy individuals, some polyreactive/self-reactive transitional B cells survive tolerance 
checkpoints to become polyreactive Breg cells. In patients with SSc, however, tolerance at 
the T1-T2 stage is defective leading to the eventual expansion of potentially-pathogenic IL-6-
producing B cells, some with specificity for Scl-70. The dotted arrows represent where 
defective selection could occur. 
 
SUPPLENETARY FIGURES AND TABLE 
 
Figure 1: The frequency of IL-10+ B cells and IL-10 production in HCs and SSc 
patients. A) The left panel shows a FACS quadrants depicting IL-10+ B cells in one HC and 
one SSc patient. IL-10+ B cells were identified following activation through CD40 by co-
culture of the cells for 72 hours on plates pre-coated with mitomycin C-treated L-fibroblasts 
transfected with human DC40L cDNA. The histogram on the right summarises the frequency 
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transitional, mature and memory B cells. The histogram on the right summarises % of IL-10+ 
B cells. C) Percentage of IL-10+ T1, T2, T3 and CD27+ transitional B cells in 8 HCs and 10 
SSc patients. D) A histogram summarising results of quantifying IL-10 production by B cells. 
The B cells were from 4 HCs and 10 SSc patients. The cells were enriched and cultured for 
72hr either with mitomycin C-treated mouse L-fibroblast expressing human CD40L alone, 
activated through TLR9 or activated with a combination of anti-CD40 mAb and CpG-ODN. 
The level of IL-10 was determined using MSD Multiplex kits. * indicates p<0.05, ** p<0.01, 
ns: non-significant using Student’s t-test. 
 
Figure 2: IL-6 expression in total B cells and B cell subsets in HCs and patients with 
limited and diffuse SSc. A) Bar chart summarising the frequency of IL-6+ ex vivo B cells 
from the blood of HCs and patients with limited and diffuse SSc. B) Bar chart summarising 
the frequency of IL-6+ T1, T2, T3 and CD27+ transitional B cell subsets. The results are 
presented as the Mean+SEM IL-6+ B cells in the blood of 9 HCs, 4 patients with limited SSc 
and 7 patients with diffuse SSc. * indicates p<0.05, ** p<0.01, ns: non-significant for 
statistical differences between the groups using the Student’s t test. 
 
Table 1: The epidemiological, serological profiles and the major internal organ involvement 
in the SSc patient cohort studied.  Abbreviations: Anti-Scl-70: Anti-scleroderma-70 
antibodies; Anti-U3RNP: Anti-U3 ribonucleoprotein antibodies; Anti-U1RNP: Anti-U1 
ribonucleoprotein antibodies; Anti-Jo1 antibodies: Anti-aminoacyl tRNA synthetase 
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